Stempoint Capital LP Sells 329,125 Shares of Dyne Therapeutics, Inc. $DYN

Stempoint Capital LP reduced its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 39.4% in the 1st quarter, HoldingsChannel reports. The fund owned 506,075 shares of the company’s stock after selling 329,125 shares during the period. Dyne Therapeutics comprises approximately 1.7% of Stempoint Capital LP’s holdings, making the stock its 18th biggest position. Stempoint Capital LP’s holdings in Dyne Therapeutics were worth $9,175,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of DYN. Creative Planning lifted its holdings in shares of Dyne Therapeutics by 6.8% during the third quarter. Creative Planning now owns 15,527 shares of the company’s stock worth $196,000 after purchasing an additional 986 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after purchasing an additional 1,440 shares during the period. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the first quarter valued at $26,000. Caxton Associates LLP raised its position in Dyne Therapeutics by 10.9% during the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after purchasing an additional 1,627 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its position in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after purchasing an additional 2,465 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Insider Activity

In related news, Director Jason P. Rhodes sold 480,240 shares of the company’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $22.79, for a total transaction of $10,944,669.60. Following the sale, the director owned 875,912 shares in the company, valued at $19,962,034.48. This represents a 35.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders bought 9,000 shares of company stock valued at $156,800 and sold 1,665,542 shares valued at $36,321,576. 9.46% of the stock is owned by corporate insiders.

Dyne Therapeutics Price Performance

DYN stock opened at $25.10 on Thursday. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -7.80 and a beta of 1.06. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a 12-month low of $9.32 and a 12-month high of $26.26. The company’s fifty day simple moving average is $20.91 and its 200 day simple moving average is $18.77.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.34). On average, analysts expect that Dyne Therapeutics, Inc. will post -3.01 earnings per share for the current year.

Wall Street Analyst Weigh In

DYN has been the topic of a number of analyst reports. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Cantor Fitzgerald assumed coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They issued an “overweight” rating on the stock. Finally, TD Cowen assumed coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.